GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (OTCPK:ORXOY) » Definitions » Piotroski F-Score

ORXOY (Orexo AB) Piotroski F-Score : 4 (As of Mar. 23, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Orexo AB Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Orexo AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Orexo AB's Piotroski F-Score or its related term are showing as below:

ORXOY' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Orexo AB was 8. The lowest was 2. And the median was 4.


Orexo AB Piotroski F-Score Historical Data

The historical data trend for Orexo AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Piotroski F-Score Chart

Orexo AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 3.00 4.00 4.00

Orexo AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 4.00 5.00 4.00

Competitive Comparison of Orexo AB's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Orexo AB's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was -0.855 + -3.423 + -4.096 + -10.578 = $-18.95 Mil.
Cash Flow from Operations was -1.815 + -0.62 + -1.31 + 0.564 = $-3.18 Mil.
Revenue was 13.38 + 14.685 + 13.344 + 14.593 = $56.00 Mil.
Gross Profit was 12.102 + 13.131 + 11.379 + 12.563 = $49.18 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(76.685 + 79.711 + 73.739 + 68.14 + 54.147) / 5 = $70.4844 Mil.
Total Assets at the begining of this year (Dec23) was $76.69 Mil.
Long-Term Debt & Capital Lease Obligation was $42.42 Mil.
Total Current Assets was $40.64 Mil.
Total Current Liabilities was $21.04 Mil.
Net Income was -6.099 + -1.17 + -3.004 + -1.813 = $-12.09 Mil.

Revenue was 15.158 + 14.644 + 14.082 + 16.183 = $60.07 Mil.
Gross Profit was 12.419 + 13.047 + 12.025 + 14.224 = $51.72 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(106.861 + 90.614 + 86.07 + 78.396 + 76.685) / 5 = $87.7252 Mil.
Total Assets at the begining of last year (Dec22) was $106.86 Mil.
Long-Term Debt & Capital Lease Obligation was $44.15 Mil.
Total Current Assets was $44.74 Mil.
Total Current Liabilities was $25.66 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Orexo AB's current Net Income (TTM) was -18.95. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Orexo AB's current Cash Flow from Operations (TTM) was -3.18. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-18.952/76.685
=-0.2471409

ROA (Last Year)=Net Income/Total Assets (Dec22)
=-12.086/106.861
=-0.1131002

Orexo AB's return on assets of this year was -0.2471409. Orexo AB's return on assets of last year was -0.1131002. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Orexo AB's current Net Income (TTM) was -18.95. Orexo AB's current Cash Flow from Operations (TTM) was -3.18. ==> -3.18 > -18.95 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=42.421/70.4844
=0.60184949

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=44.153/87.7252
=0.50331034

Orexo AB's gearing of this year was 0.60184949. Orexo AB's gearing of last year was 0.50331034. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=40.637/21.038
=1.93159996

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=44.738/25.659
=1.74355976

Orexo AB's current ratio of this year was 1.93159996. Orexo AB's current ratio of last year was 1.74355976. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Orexo AB's number of shares in issue this year was 34.481. Orexo AB's number of shares in issue last year was 34.444. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=49.175/56.002
=0.87809364

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=51.715/60.067
=0.86095527

Orexo AB's gross margin of this year was 0.87809364. Orexo AB's gross margin of last year was 0.86095527. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=56.002/76.685
=0.73028624

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=60.067/106.861
=0.56210404

Orexo AB's asset turnover of this year was 0.73028624. Orexo AB's asset turnover of last year was 0.56210404. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Orexo AB has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Orexo AB  (OTCPK:ORXOY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Orexo AB Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Orexo AB's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Orexo AB Business Description

Traded in Other Exchanges
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.